Skip to main content
Top
Published in: BMC Gastroenterology 1/2009

Open Access 01-12-2009 | Research article

Limitations of the MELD score in predicting mortality or need for removal from waiting list in patients awaiting liver transplantation

Authors: Daniel Gotthardt, Karl Heinz Weiss, Melanie Baumgärtner, Alexandra Zahn, Wolfgang Stremmel, Jan Schmidt, Thomas Bruckner, Peter Sauer

Published in: BMC Gastroenterology | Issue 1/2009

Login to get access

Abstract

Background

Decompensated cirrhosis is associated with a poor prognosis and liver transplantation provides the only curative treatment option with excellent long-term results. The relative shortage of organ donors renders the allocation algorithms of organs essential. The optimal strategy based on scoring systems and/or waiting time is still under debate.

Methods

Data sets of 268 consecutive patients listed for single-organ liver transplantation for nonfulminant liver disease between 2003 and 2005 were included into the study. The Model for End-Stage Liver Disease (MELD) and Child-Turcotte-Pugh (CTP) scores of all patients at the time of listing were used for calculation. The predictive ability not only for mortality on the waiting list but also for the need for withdrawal from the waiting list was calculated for both scores. The Mann-Whitney-U Test was used for the univariate analysis and the AUC-Model for discrimination of the scores.

Results

In the univariate analysis comparing patients who are still on the waiting list and patients who died or were removed from the waiting list due to poor conditions, the serum albumin, bilirubin INR, and CTP and MELD scores as well as the presence of ascites and encephalopathy were significantly different between the groups (p < 0.05), whereas serum creatinine and urea showed no difference.
Comparing the predictive abilities of CTP and MELD scores, the best discrimination between patients still alive on the waiting list and patients who died on or were removed from the waiting list was achieved at a CTP score of ≥9 and a MELD score of ≥14.4. The sensitivity and specificity to identify mortality or severe deterioration for CTP was 69.0% and 70.5%, respectively; for MELD, it was 62.1% and 72.7%, respectively. This result was supported by the AUC analysis showing a strong trend for superiority of CTP over MELD scores (AUROC 0.73 and 0.68, resp.; p = 0.091).

Conclusion

The long term prediction of mortality or removal from waiting list in patients awaiting liver transplantation might be better assessed by the CTP score than the MELD score. This might have implications for the development of new improved scoring systems.
Appendix
Available only for authorised users
Literature
1.
go back to reference Christensen E: Prognostic models including the Child-Pugh, MELD and Mayo risk scores--where are we and where should we go?. J Hepatol. 2004, 41: 344-50. 10.1016/j.jhep.2004.06.005.CrossRefPubMed Christensen E: Prognostic models including the Child-Pugh, MELD and Mayo risk scores--where are we and where should we go?. J Hepatol. 2004, 41: 344-50. 10.1016/j.jhep.2004.06.005.CrossRefPubMed
2.
go back to reference Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R: Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973, 60: 646-9. 10.1002/bjs.1800600817.CrossRefPubMed Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R: Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973, 60: 646-9. 10.1002/bjs.1800600817.CrossRefPubMed
3.
go back to reference Durand F, Valla D: Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J Hepatol. 2005, 42 (Suppl): S100-7. 10.1016/j.jhep.2004.11.015.CrossRefPubMed Durand F, Valla D: Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J Hepatol. 2005, 42 (Suppl): S100-7. 10.1016/j.jhep.2004.11.015.CrossRefPubMed
4.
go back to reference Wiesner RH: Patient selection in an era of donor liver shortage: current US policy. Nat Clin Pract Gastroenterol Hepatol. 2005, 2: 24-30. 10.1038/ncpgasthep0070.CrossRefPubMed Wiesner RH: Patient selection in an era of donor liver shortage: current US policy. Nat Clin Pract Gastroenterol Hepatol. 2005, 2: 24-30. 10.1038/ncpgasthep0070.CrossRefPubMed
5.
go back to reference Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC: A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000, 31: 864-71. 10.1053/he.2000.5852.CrossRefPubMed Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC: A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000, 31: 864-71. 10.1053/he.2000.5852.CrossRefPubMed
6.
go back to reference Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, Dickson ER, Kim WR: A model to predict survival in patients with end-stage liver disease. Hepatology. 2001, 33: 464-70. 10.1053/jhep.2001.22172.CrossRefPubMed Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, Dickson ER, Kim WR: A model to predict survival in patients with end-stage liver disease. Hepatology. 2001, 33: 464-70. 10.1053/jhep.2001.22172.CrossRefPubMed
7.
go back to reference Cholongitas E, Marelli L, Kerry A, Senzolo M, Goodier DW, Nair D, Thomas M, Patch D, Burroughs AK: Different methods of creatinine measurement significantly affect MELD scores. Liver Transpl. 2007, 13: 523-9. 10.1002/lt.20994.CrossRefPubMed Cholongitas E, Marelli L, Kerry A, Senzolo M, Goodier DW, Nair D, Thomas M, Patch D, Burroughs AK: Different methods of creatinine measurement significantly affect MELD scores. Liver Transpl. 2007, 13: 523-9. 10.1002/lt.20994.CrossRefPubMed
8.
go back to reference Robert A, Chazouilleres O: Prothrombin time in liver failure: time, ratio, activity percentage, or international normalized ratio?. Hepatology. 1996, 24: 1392-4. 10.1002/hep.510240613.CrossRefPubMed Robert A, Chazouilleres O: Prothrombin time in liver failure: time, ratio, activity percentage, or international normalized ratio?. Hepatology. 1996, 24: 1392-4. 10.1002/hep.510240613.CrossRefPubMed
9.
go back to reference Trotter JF, Brimhall B, Arjal R, Phillips C: Specific laboratory methodologies achieve higher model for endstage liver disease (MELD) scores for patients listed for liver transplantation. Liver Transpl. 2004, 10: 995-1000. 10.1002/lt.20195.CrossRefPubMed Trotter JF, Brimhall B, Arjal R, Phillips C: Specific laboratory methodologies achieve higher model for endstage liver disease (MELD) scores for patients listed for liver transplantation. Liver Transpl. 2004, 10: 995-1000. 10.1002/lt.20195.CrossRefPubMed
10.
go back to reference Fink MA, Berry SR, Gow PJ, Angus PW, Wang BZ, Muralidharan V, Christophi C, Jones RM: Risk factors for liver transplantation waiting list mortality. J Gastroenterol Hepatol. 2007, 22: 119-24. 10.1111/j.1440-1746.2006.04422.x.CrossRefPubMed Fink MA, Berry SR, Gow PJ, Angus PW, Wang BZ, Muralidharan V, Christophi C, Jones RM: Risk factors for liver transplantation waiting list mortality. J Gastroenterol Hepatol. 2007, 22: 119-24. 10.1111/j.1440-1746.2006.04422.x.CrossRefPubMed
11.
go back to reference Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, Kremers W, Lake J, Howard T, Merion RM, et al: Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003, 124: 91-6. 10.1053/gast.2003.50016.CrossRefPubMed Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, Kremers W, Lake J, Howard T, Merion RM, et al: Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003, 124: 91-6. 10.1053/gast.2003.50016.CrossRefPubMed
12.
go back to reference Huo TI, Wu JC, Lin HC, Lee FY, Hou MC, Lee PC, Chang FY, Lee SD: Evaluation of the increase in model for end-stage liver disease (DeltaMELD) score over time as a prognostic predictor in patients with advanced cirrhosis: risk factor analysis and comparison with initial MELD and Child-Turcotte-Pugh score. J Hepatol. 2005, 42: 826-32. 10.1016/j.jhep.2005.01.019.CrossRefPubMed Huo TI, Wu JC, Lin HC, Lee FY, Hou MC, Lee PC, Chang FY, Lee SD: Evaluation of the increase in model for end-stage liver disease (DeltaMELD) score over time as a prognostic predictor in patients with advanced cirrhosis: risk factor analysis and comparison with initial MELD and Child-Turcotte-Pugh score. J Hepatol. 2005, 42: 826-32. 10.1016/j.jhep.2005.01.019.CrossRefPubMed
13.
go back to reference Heuman DM, Mihas A: Utility of the MELD score for assessing 3-month survival in patients with liver cirrhosis: one more positive answer. Gastroenterology. 2003, 125: 992-3. 10.1016/S0016-5085(03)01149-1. author reply 994-5CrossRefPubMed Heuman DM, Mihas A: Utility of the MELD score for assessing 3-month survival in patients with liver cirrhosis: one more positive answer. Gastroenterology. 2003, 125: 992-3. 10.1016/S0016-5085(03)01149-1. author reply 994-5CrossRefPubMed
14.
go back to reference Merion RM, Schaubel DE, Dykstra DM, Freeman RB, Port FK, Wolfe RA: The survival benefit of liver transplantation. Am J Transplant. 2005, 5: 307-13. 10.1111/j.1600-6143.2004.00703.x.CrossRefPubMed Merion RM, Schaubel DE, Dykstra DM, Freeman RB, Port FK, Wolfe RA: The survival benefit of liver transplantation. Am J Transplant. 2005, 5: 307-13. 10.1111/j.1600-6143.2004.00703.x.CrossRefPubMed
15.
go back to reference Ruf AE, Kremers WK, Chavez LL, Descalzi VI, Podesta LG, Villamil FG: Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl. 2005, 11: 336-43. 10.1002/lt.20329.CrossRefPubMed Ruf AE, Kremers WK, Chavez LL, Descalzi VI, Podesta LG, Villamil FG: Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl. 2005, 11: 336-43. 10.1002/lt.20329.CrossRefPubMed
16.
go back to reference Said A, Williams J, Holden J, Remington P, Gangnon R, Musat A, Lucey MR: Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol. 2004, 40: 897-903. 10.1016/S0168-8278(04)00064-9.CrossRefPubMed Said A, Williams J, Holden J, Remington P, Gangnon R, Musat A, Lucey MR: Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol. 2004, 40: 897-903. 10.1016/S0168-8278(04)00064-9.CrossRefPubMed
17.
go back to reference Biggins SW, Rodriguez HJ, Bacchetti P, Bass NM, Roberts JP, Terrault NA: Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology. 2005, 41: 32-9. 10.1002/hep.20517.CrossRefPubMed Biggins SW, Rodriguez HJ, Bacchetti P, Bass NM, Roberts JP, Terrault NA: Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology. 2005, 41: 32-9. 10.1002/hep.20517.CrossRefPubMed
18.
go back to reference Heuman DM, Abou-Assi SG, Habib A, Williams LM, Stravitz RT, Sanyal AJ, Fisher RA, Mihas AA: Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology. 2004, 40: 802-10.CrossRefPubMed Heuman DM, Abou-Assi SG, Habib A, Williams LM, Stravitz RT, Sanyal AJ, Fisher RA, Mihas AA: Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology. 2004, 40: 802-10.CrossRefPubMed
19.
go back to reference Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, Edwards E, Therneau TM: Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008, 359: 1018-26. 10.1056/NEJMoa0801209.CrossRefPubMedPubMedCentral Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, Edwards E, Therneau TM: Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008, 359: 1018-26. 10.1056/NEJMoa0801209.CrossRefPubMedPubMedCentral
20.
go back to reference Merion RM, Wolfe RA, Dykstra DM, Leichtman AB, Gillespie B, Held PJ: Longitudinal assessment of mortality risk among candidates for liver transplantation. Liver Transpl. 2003, 9: 12-8. 10.1053/jlts.2003.50009.CrossRefPubMed Merion RM, Wolfe RA, Dykstra DM, Leichtman AB, Gillespie B, Held PJ: Longitudinal assessment of mortality risk among candidates for liver transplantation. Liver Transpl. 2003, 9: 12-8. 10.1053/jlts.2003.50009.CrossRefPubMed
21.
go back to reference Bambha K, Kim WR, Kremers WK, Therneau TM, Kamath PS, Wiesner R, Rosen CB, Thostenson J, Benson JT, Dickson ER: Predicting survival among patients listed for liver transplantation: an assessment of serial MELD measurements. Am J Transplant. 2004, 4: 1798-804. 10.1111/j.1600-6143.2004.00550.x.CrossRefPubMed Bambha K, Kim WR, Kremers WK, Therneau TM, Kamath PS, Wiesner R, Rosen CB, Thostenson J, Benson JT, Dickson ER: Predicting survival among patients listed for liver transplantation: an assessment of serial MELD measurements. Am J Transplant. 2004, 4: 1798-804. 10.1111/j.1600-6143.2004.00550.x.CrossRefPubMed
Metadata
Title
Limitations of the MELD score in predicting mortality or need for removal from waiting list in patients awaiting liver transplantation
Authors
Daniel Gotthardt
Karl Heinz Weiss
Melanie Baumgärtner
Alexandra Zahn
Wolfgang Stremmel
Jan Schmidt
Thomas Bruckner
Peter Sauer
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2009
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/1471-230X-9-72

Other articles of this Issue 1/2009

BMC Gastroenterology 1/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.